Incorporation of adjuvant therapy into the multimodality management of gastrointestinal stromal tumors of the stomach in the United States

Annals of Surgical Oncology

Volumn 19, Issue 1, 2012, Pages 184-191

  Bilimoria, Karl Y ^a,b   Wayne, Jeffrey D ^b   Merkow, Ryan P ^b   Abbott, Daniel E ^a   Cormier, Janice N ^a   Feig, Barry W ^a   Hunt, Kelly K ^a   Pisters, Peter W T ^a   Pollock, Raphael ^a   Bentrem, David J ^b,c  

^a UNIVERSITY OF TEXAS   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; REGRESSION ANALYSIS; TUMOR VOLUME; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE MANAGEMENT; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; PIPERAZINES; PROGNOSIS; PYRIMIDINES; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84856638055     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1842-9     Document Type: Article

References (49)

1. BJ Druker S Tamura E Buchdunger S Ohno GM Segal S Fanning, et al. 1996 Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 561 566 8616716 10.1038/nm0596-561 1:CAS:528:DyaK28Xislyhs70%3D
2. BJ Druker M Talpaz DJ Resta B Peng E Buchdunger JM Ford, et al. 2001 Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 1031 1037 11287972 10.1056/NEJM200104053441401 1:CAS:528:DC%2BD3MXivFGnu70%3D
3. M Lemonick A Park D Cray C Gorman 2001 New hope for cancer Time 157 62 69 11393038 1:STN:280:DC%2BD3MzhslKgtA%3D%3D
4. Blanke CD, von Mehren M, Joensuu H, Roberts PJ, et al. Evaluation of the safety and efficacy of an oral molecularly-targeted, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors expressing C-KIT (CD117). Proc Am Soc Clin Oncol. 2001 (abstr 1).
5. H Joensuu PJ Roberts M Sarlomo-Rikala LC Andersson P Tervahartiala D Tuveson, et al. 2001 Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 1052 1056 11287975 10.1056/NEJM200104053441404 1:STN:280:DC%2BD3M3gvVekuw%3D%3D
6. GD Demetri M von Mehren CD Blanke AD Van den Abbeele B Eisenberg PJ Roberts, et al. 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472 480 12181401 10.1056/NEJMoa020461 1:CAS:528:DC%2BD38XmtV2nt7s%3D
7. CD Blanke GD Demetri M von Mehren MC Heinrich B Eisenberg JA Fletcher, et al. 2008 Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT J Clin Oncol 26 620 625 18235121 10.1200/JCO.2007.13.4403 1:CAS:528:DC%2BD1cXis1alsL0%3D
8. CD Blanke C Rankin GD Demetri CW Ryan M von Mehren RS Benjamin, et al. 2008 Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 J Clin Oncol 26 626 632 18235122 10.1200/JCO.2007.13.4452 1:CAS:528:DC%2BD1cXis1alsLs%3D
9. J Verweij PG Casali J Zalcberg A LeCesne P Reichardt JY Blay, et al. 2004 Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 1127 1134 15451219 10.1016/S0140-6736(04) 17098-0 1:CAS:528:DC%2BD2cXnvVOiu7o%3D
10. DeMatteo RP, Owzar K, Antonescu CR, Maki R, Demetri D, McCarter M, et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U.S. Intergroup phase II trial ACOSOG Z9000. Proc Am Soc Clin Oncol. 2008 (abstr 8).
11. RP Dematteo KV Ballman CR Antonescu RG Maki PW Pisters GD Demetri, et al. 2009 Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial Lancet 373 1097 1104 19303137 10.1016/S0140-6736(09)60500-6 1:CAS:528:DC%2BD1MXjslOltro%3D
12. DeMatteo RP, Owzar K, Maki R, Pisters P, Blackstein M, Antonescu C, et al. Adjuvant imatinib mesylate increases recurrence free survival in patients with completely resected localized primary gastrointestinal stromal tumor: North American Intergroup Phase III trial ACOSOG Z9001. Proc Am Soc Clin Oncol. 2007 (abstract 10079).
13. BL Eisenberg J Harris CD Blanke GD Demetri MC Heinrich JC Watson, et al. 2009 Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665 J Surg Oncol 99 42 47 18942073 10.1002/jso.21160 1:CAS:528:DC%2BD1MXhvFCjur0%3D
14. JC McAuliffe KK Hunt AJ Lazar H Choi W Qiao P Thall, et al. 2009 A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis Ann Surg Oncol 16 910 919 18953611 10.1245/s10434-008-0177-7
15. GD Demetri M von Mehren CR Antonescu RP DeMatteo KN Ganjoo RG Maki, et al. 2010 NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors J Natl Compr Cancer Netw 8 Suppl 2 S1 S41 1:CAS:528:DC%2BC3cXlvFOls7g%3D quiz S42-4
16. Balas E, Boren S. Managing clinical knowledge for health care improvement. In: Bemmel J, Mc Cray AT, editors. Yearbook of medical informatics 2000: patient-centered systems. Stuttgart: Schattauer; 2000. p. 65-70.
17. KY Bilimoria AK Stewart DP Winchester CY Ko 2008 The National Cancer Data Base: a powerful initiative to improve cancer care in the United States Ann Surg Oncol 15 683 690 18183467 10.1245/s10434-007-9747-3
18. DP Winchester AK Stewart C Bura RS Jones 2004 The National Cancer Data Base: a clinical surveillance and quality improvement tool J Surg Oncol 85 1 3 14696080 10.1002/jso.10320
19. KY Bilimoria DJ Bentrem AK Stewart DP Winchester CY Ko 2009 Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base J Clin Oncol 27 4177 4181 19636004 10.1200/JCO.2008.21.7018
20. International Classification of Disease for Oncology. 3rd ed. Geneva: World Health Organization, 2000.
21. Facility Oncology Registry Data Standards. Chicago: Commission on Cancer, 2004.
22. Department of Health and Human Services. The International Classification of Diseases. 9th revised. clinical modification: ICD-9-CM. Washington, DC: Government Printing Office, 1998.
23. ME Charlson P Pompei KL Ales CR MacKenzie 1987 A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 373 383 3558716 10.1016/0021-9681(87)90171-8 1:STN:280:DyaL2s7ms1GnsQ%3D%3D
24. RA Deyo DC Cherkin MA Ciol 1992 Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases J Clin Epidemiol 45 613 619 1607900 10.1016/0895-4356(92)90133-8 1:STN:280:DyaK38zgtVeqsA%3D%3D
25. Commission on Cancer: Approvals Categories. Available at http://www.facs.org/cancer/coc/categories.html. Accessed December 17, 2006.
26. KS Panageas D Schrag E Riedel PB Bach CB Begg 2003 The effect of clustering of outcomes on the association of procedure volume and surgical outcomes Ann Intern Med 139 658 665 14568854
27. Hosmer J, Lemeshow S. Applied logistic regression. New York: Wiley, 1999.
28. Eckhauser F, Yahanda A, Greenson J. Gastric smooth muscle tumors. In: Cameron J, editor. Current surgical therapy, 3rd ed. St. Louis: Mosby; 1998. p. 114-7.
29. CD Fletcher JJ Berman C Corless, et al. 2002 Diagnosis of gastrointestinal stromal tumors: a consensus approach Hum Pathol 33 459 465 12094370 10.1053/hupa.2002.123545
30. Miettinen M, El-Rifai W, Sobin LH, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol. 2002;33:478-83.
31. M Miettinen J Lasota 2006 Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis Arch Pathol Lab Med 130 1466 1478 17090188 1:CAS:528:DC%2BD28XhtFyhs7%2FN
32. DM Huse M von Mehren G Lenhart H Joensuu C Blanke W Feng, et al. 2007 Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours Clin Drug Investig 27 85 93 17217313 10.2165/00044011-200727020-00001 1:CAS:528:DC%2BD2sXis1yntLg%3D
33. H Joensuu JC Trent P Reichardt 2011 Practical management of tyrosine kinase inhibitor-associated side effects in GIST Cancer Treat Rev 37 75 88 20570050 10.1016/j.ctrv.2010.04.008 1:CAS:528:DC%2BC3cXhsFajs7vJ
34. MC Heinrich RG Maki CL Corless CR Antonescu A Harlow D Griffith, et al. 2008 Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor J Clin Oncol 26 5352 5359 18955458 10.1200/JCO.2007.15.7461 1:CAS:528:DC%2BD1MXhslCmtQ%3D%3D
35. M Van Glabbeke J Verweij PG Casali A Le Cesne P Hohenberger I Ray-Coquard, et al. 2005 Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study J Clin Oncol 23 5795 5804 16110036 10.1200/JCO.2005.11.601
36. JS Gold RP Dematteo 2007 Neoadjuvant therapy for gastrointestinal stromal tumor (GIST): racing against resistance Ann Surg Oncol 14 1247 1248 17265116 10.1245/s10434-006-9291-6
37. KY Bilimoria DJ Bentrem JM Feinglass AK Stewart DP Winchester MS Talamonti, et al. 2008 Directing surgical quality improvement initiatives: comparison of perioperative mortality and long-term survival for cancer surgery J Clin Oncol 26 4626 4633 18574159 10.1200/JCO.2007.15.6356
38. JD Birkmeyer Y Sun SL Wong TA Stukel 2007 Hospital volume and late survival after cancer surgery Ann Surg 245 777 783 17457171 10.1097/01.sla. 0000252402.33814.dd
39. KY Bilimoria DJ Bentrem CY Ko AK Stewart DP Winchester MS Talamonti 2007 National failure to operate on early stage pancreatic cancer Ann Surg 246 173 180 17667493 10.1097/SLA.0b013e3180691579
40. KY Bilimoria CM Balch DJ Bentrem MS Talamonti CY Ko JR Lange, et al. 2008 Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States Ann Surg Oncol 15 1566 1576 18414952 10.1245/s10434-008-9885-2
41. KY Bilimoria DJ Bentrem CY Ko JS Tomlinson AK Stewart DP Winchester, et al. 2007 Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume Cancer 110 1227 1234 17654662 10.1002/cncr.22916
42. KY Bilimoria CM Balch JD Wayne DC Chang BE Palis SM Dy, et al. 2009 Health care system and socioeconomic factors associated with variance in use of sentinel lymph node biopsy for melanoma in the United States J Clin Oncol 27 1857 1863 19273706 10.1200/JCO.2008.18.7567
43. RH Andtbacka CS Ng CL Scaife JN Cormier KK Hunt PW Pisters, et al. 2007 Surgical resection of gastrointestinal stromal tumors after treatment with imatinib Ann Surg Oncol 14 14 24 17072676 10.1245/s10434-006-9034-8
44. JZ Ayanian AM Zaslavsky CS Fuchs E Guadagnoli CM Creech RD Cress, et al. 2003 Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort J Clin Oncol 21 1293 1300 12663717 10.1200/JCO.2003.06.178
45. RD Cress AM Zaslavsky DW West RE Wolf MC Felter JZ Ayanian 2003 Completeness of information on adjuvant therapies for colorectal cancer in population-based cancer registries Med Care 41 1006 1012 12972840 10.1097/01.MLR.0000083740.12949.88
46. XL Du CR Key L Dickie R Darling GL Delclos K Waller, et al. 2006 Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviews J Clin Epidemiol 59 53 60 16360561 10.1016/j.jclinepi.2005.06.002
47. JL Rubin DC Taylor M Sanon JH Coombs VK Bollu 2010 Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors J Manag Care Pharm 16 482 491 20726677
48. MA Schuster EA McGlynn RH Brook 2005 How good is the quality of health care in the United States? Milbank Q 83 843 895 16279970 10.1111/j.1468-0009. 2005.00403.x
49. RH Brook 2009 Assessing the appropriateness of care-its time has come JAMA 302 997 998 19724048 10.1001/jama.2009.1279 1:CAS:528:DC%2BD1MXhtVOlu7jN